News

AxxessBio is pleased to announce that Health Sciences Authority (HSA) Singapore has granted the registration rights to supply TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 15mg with the following indications: With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in

October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®.   Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon.   Apnea in preterm infants is common in babies born at less

October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma  SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare metabolic diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease.  

On August 1st 2020 AxxessBio and Cycle Pharmaceuticals entered into an exclusive agreement for the distribution of NITYR® (nitisinone) tablets in Singapore, Thailand, Brunei, Philippines, Macau and Hong Kong. NITYR® does not have marketing authorization in these territories however it is being made available  through Name Patient Programs. These programs  differ